What this means
This is a plan for a 12-week study, not a finished one. It has not started recruiting people, and no results have been posted yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 45–75
- Where
- 1 site, including North Carolina
The science
- Registered title
- Vibegron for ENergy Thinking and Resilience in Aging
- Trial ID
- NCT06987383 ↗
- Phase
- PHASE 3
- Study type
- interventional
- Conditions
- Obesity
- What is tested
- Vibegron, Placebo
- Sponsor
- Wake Forest University Health Sciences
- Ages
- 45 Years to 75 Years
- Dates
- First posted May 23, 2025 · updated Sep 29, 2026
Registry summary
This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.
Sites (1)
- Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States